ANA-Negative Hydralazine-Induced Pericardial Effusion
Joint Authors
Zeitjian, Vicken
Mehdizadeh, Azar
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-12-17
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
This case describes a patient with pericardial effusion as a phenomenon of the drug-induced lupus erythematosus (DILE) syndrome due to hydralazine.
The relevance of this case report lies in the fact that although hydralazine has been a known causative agent of DILE, its presentation may involve a negative anti-nuclear antibody (ANA) study.
Pericardial effusion is a documented adverse effect as a result of hydralazine use.
It is typically common to screen for DILE with the serum ANA test prior to proceeding to more costly and specific tests (i.e., anti-histone antibody).
As per our literature review, this is the second case of hydralazine causing DILE with a negative ANA.
As in our case, although the screening serum ANA is the initial next best step for suspicion of DILE by hydralazine, it is important to consider the diagnosis without ANA positivity.
American Psychological Association (APA)
Zeitjian, Vicken& Mehdizadeh, Azar. 2017. ANA-Negative Hydralazine-Induced Pericardial Effusion. Case Reports in Medicine،Vol. 2017, no. 2017, pp.1-3.
https://search.emarefa.net/detail/BIM-1146675
Modern Language Association (MLA)
Zeitjian, Vicken& Mehdizadeh, Azar. ANA-Negative Hydralazine-Induced Pericardial Effusion. Case Reports in Medicine No. 2017 (2017), pp.1-3.
https://search.emarefa.net/detail/BIM-1146675
American Medical Association (AMA)
Zeitjian, Vicken& Mehdizadeh, Azar. ANA-Negative Hydralazine-Induced Pericardial Effusion. Case Reports in Medicine. 2017. Vol. 2017, no. 2017, pp.1-3.
https://search.emarefa.net/detail/BIM-1146675
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1146675